Tramadol potentiates chemotherapy efficacy in hepatocellular carcinoma cells.
Fan Hsiu-Lung HL, Liu Shu-Ting ST, Wu Zih-Syuan ZS, Huang Yi-Hsuan YH et al.
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer-related deaths, leading to poor responses to chemotherapy. Cancer-related pain affects up to 90% of these patients, significantly impairing their quality of life. Tramadol, a prescribed analgesic for cancer pain, has shown anti-tumour effects in various malignancies, yet its potential in HCC remains largely unexplored. In this study, we investigated tramadol's anti-proliferative, pro-apoptotic, and autophagy-inducing effects in HepG2, Hep3B, and Huh7 cell lines. Tramadol significantly inhibits cell proliferation in a dose-dependent manner, leading to a reduction in the S-phase and subG1 phase accumulation. It induces apoptosis in HepG2 and Hep3B, increases late apoptosis/necrosis, and enhances autophagy. Additionally, tramadol increased the cytotoxicity of cisplatin and 5-fluorouracil, with significant reductions in their IC50 values. Overall, tramadol inhibits HCC growth, promotes apoptosis, and enhances chemotherapy efficacy, suggesting it could be a dual-benefit therapeutic strategy for HCC.